Enzyme variability and neonatal jaundice. The role of adenosine deaminase and acid phosphatase by Lepore, Alessandro et al.




Enzyme variability and neonatal jaundice. The role of adenosine
deaminase and acid phosphatase
Alessandro Lepore1, N. Lucarini2, M. A. Evangelista1, G. Palombaro3, A. Londrillo4,
P. BaUarini2, P. Borgiani2, R Gloria-Bottini5, and Egidio Bottini5
JCenter of Hygiene and Preventive Medicine, U.L.S.S., Penne, laboratory of
Genetics, University of Camerino, School of Science, Camerino, 3Department of
Obstetrics and Gynecology, U.L.S.S., Penne, 4Department of Pediatrics, U.L.S.S.,
Penne, 5Chair of Human Development, 2nd University of Rome, School of Medicine,
Rome, Italy
1 Introduction
In a recent paper we have reported an interaction
between ACPj (Erythrocyte acid phosphatase EC
3.1.3.2.) and ADA (Adenosine deaminase EC
3.5.4.4.) in relation to neonatal hyperbilirubine-
mia. The incidence of jaundice was much higher
among newborn of ACPi phenotype BA carrying
ADA2 allele (41.7%) than among other infants
(7.5%) [3]. We have now studied a new series of
infants from another population: the data confirm
that ACPi phenotype BA carrying ADA2 allele
has a very high risk of clinically relevant neonatal
jaundice.
It is likely that both environmental and genetic
factors influence the severity of "physiologic jaun-
dice of newborn". As in many pathologic situa-
tions in which a multifactorial inheritance is pre-
sumed, research should be directed toward those
factors which determine the "normal variability"
of biochemical and physiological parameters. Hu-
man genetic polymorphisms are therefore the most
important candidates for this kind of investiga-
tions.
ACPi is an enzyme found in the cytoplasm of
many tissues besides red blood cells. It is geneti-
cally distinct from acid phosphatases found in
lysosomes and is polymorphic with three codomi-
nant alleles (PA, PB and Pc) at an autosomal locus
[11,12, 20]. ACPi probably acts in vivo as a flavin
mononuclectide phosphatase [14, 15, 17]. It may
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therefore modulate Krebs-cycle activity and other
important enzymes such as glutathione reductase,
a flavoenzyme which exert a key role in the main-
tenance of red cell integrity [17]. Enzymatic activ-
ity of ACPi is modulated (activated or inhibited)
by purines and inhibited by folic acid. The most
important aspect of these findings is the fact that
in the quantitative variation of ACPi enzyme ac-
tivity, the contribution of the alloenzymes in-
creases in the order PA < PB < Pc [12] whereas
with the effects on purine and folic acid modula-
tion, the alloenzyme contribution is ranked either
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Pc < PA < PB or PB < PA < Pc. This difference in
ranking indicates that the two types of activity
variation represent independent effects [14].
The association previously reported [5, 6, 8] be-
tween CA phenotype and neonatal hyperbilirubi-
nemia has been tentatively explained by the fact
that activation of CA by adenine is stronger as
compared to other ACPi genotypes. This would
cause a reduced availability of flavin cofactors
(figure 1) and a lower activity of the flavo-enzyme
glutathione reductase which in turn may be re-
flected in a reduced red cell stability [14]. Since
flavoenzymes have a central role in metabolism,
modulation of coenzyme levels may have impor-
tance in many developmental processes which may
influence bilirubin metabolism. Recent observa-










Figure 1. Scheme showing the action of ACPi on flavin
cofactors metabolism. (Slightly modified from Mansfield
and Sensabough [14].)
ADA is a polymorphic enzyme which catalizes the
deamination of adenosine to inosine. Its synthesis
is controlled by an autosomal locus with two co-
dominant alleles ADA1 and ADA2. The enzymatic
activity decreases in the order ADA1 > ADA2 [1,
9, 19]. The study of possible interactions between
ACPi and ADA was suggested by the observation
that while adenosine does not show appreciable
effects of ACPi activity, inosine, on the contrary,
is a relatively strong activator [14].
2 Material and methods
2.1 Infants from the population of Penne
Penne is a small town in the East Side of Southern
Italy. It is located in a rural area, at a distance of
about two hundred kilometers from Rome. The
population is very homogeneous and immigration
is practically absent. These people are probably
the direct descendants of the ancient Italic popu-
lation called "VESTINI".
A sample of 56 children treated by phototherapy
during the neonatal period (53% of infants ob-
served in four years) were studied. All children
were born at term and weighted 2500 grams or
more. Phototherapy was started at bilirubin level
of 12 mg/dl. The proportion of full term infants
treated by phototherapy is about 15% in this
population.
A control sample of 141 newborn infants without
clinically relevant neonatal jaundice were also
studied.
2.2 Newborn infants from the population of Rome
This sample has been already reported in a pre-
vious paper [3]. Two consecutive series of infants,
born at term, weighting 2500 gr or more and
compatible with their mothers in ABO and Rh
systems, were studied. Both ADA and ACPt phen-
otypes were determined in 225 infants. Twenty one
(9.33%) were treated by phototherapy. In these
subjects, therapy was started at bilirubin levels
greater than 12 mg/dl.
ACPi and ADA phenotypes were determined by
starch gel electrophoresis [12, 19] on umbilical
cord blood (Rome) or venous blood (Penne).
3 Results
Table I shows the sample distribution of some
relevant variables in infants with neonatal jaun-
dice. In the sample from Penne, maternal age
distribution is shifted towards extreme values.
Tables II and III and figure 2 show that in both
populations BA phenotype carrying ADA2 allele
is associated with a very high incidence of clinically
relevant neonatal jaundice. However, besides this
striking similarity of the ACPi by ADA interaction
in relation to neonatal jaundice the data also show
differences between the two populations. In fact
ACPi phenotype BA not carrying ADA2 shows
an incidence of jaundice much higher in the pop-
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Table I. Jaundiced infants treated by phototherapy during neonatal period from two Italian populations. Sample
distribution of some relevant variables
Population
Number of infants































































































Table ΙΠ. Incidence of jaundice in ACPi phenotype BA in relation to presence of ADA2 allele. In the sample from
Penne the incidence was estimated taking into account the phenotype distributions in treated and not-treated infants

























Three way contineency table analysis by log-linear model [18]
X = ACP,-ADA joint phenotype FACTOR (categories: ACP, ΒΑ-ADA2 carrier/other types)
Υ : JAUNDICE FACTOR (categories: treated by phototherapy/not treated)
Ζ = POPULATION FACTOR (categories: Penne/Roma).
test G (Williams) D.F. Significance
X-Y-Z interaction
independence of factors X and Υ
given the level of Ζ
independence of factors X and Ζ
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•JAUNDICED INFANTS
Π NOT JAUNDICED INFANTS
Figure!. Incidence of ACPi phenotype BA carrying
ADA2 allele among jaundiced and not jaundiced infants.
Vertical lines represent standard errors.
ulation of Penne than in the population of Rome.
These differences may be due: (i) to ethnics back-
ground, (ii) to differences in the clinical approach
especially in the administration of phototherapy,
and (iii) to the possibility that jaundiced infants
excluded for sampling have slightly different clin-
ical characteristics as compared to infants included
in the study.
In the sample from Rome the risk of neonatal
jaundice is 41.7% for ACPi BA infants carrying
ADA2 and 7.5% for other infants. Relative risk
for ACPi BA infants carrying ADA2 is 5.55 and
attributable risk is 34.2%. In the sample from
Penne and indirect estimate gives a risk of neonatal
jaundice of 38.4% for ACPi BA infants carrying
ADA2 and 13.8% for other infants. Relative risk
is 2.78% and attributable risk 24.6%.
4 Discussion
The present data make it extremely unlikely that
the observed combined effect of ACPi and ADA
phenotypes on the incidence of neonatal jaundice
may be due to sampling chance phenomena. Since
the population of Penne is homogeneous, strati-
fication can be reasonably excluded.
The positive association of jaundice with
phenotype CA previously reported by our group
may be explained assuming that, since CA has a
relatively high activity, flavin cofactors and glu-
tathione reductase activity are reduced. This in
turn would cause a reduction of RBC survival and
an increase of bilirubin load. In subjects carrying
ADA2, however, the highest incidence of neonatal
jaundice is observed in ACPi phenotype BA. Since
ACPi BA has a low enzymatic activity and prob-
ably a relatively high levels of flavin cofactors,
some other mechanism must be assumed in order
to explain the association. ADA2 carriers produce
less inosine as compared to ADA 1 subjects and
therefore ACPt activity may be generally lower in
ADA 2-1 than in ADA 1. ACPj phenotype BA in
the presence of ADA2 might attain very low en-
zymatic activities and in turn flavoenzymes and
related metabolic pathways might have high levels
of activity. It is known that microsomal heme
oxigenase catalyses the oxidation of heme at the
oc-methene bridge to form biliverdin; this step is
subsequently coupled with soluble NADPH-de-
pendent biliverdin reductase to form bilirubin [7,
16, 21]. Concentration of cofactors produced by
metabolic pathways involving flavoenzymes may
be rate-limiting for the heme-oxigenase complex
and for the production of bilirubin in the new-
borns. Heme oxigenase activity and production of
endogeneous CO in newborns should be analysed
in relation to ACPi and ADA phenotype in order
to give support to our conjecture.
Ethnic factors may affect the severity of physio-
logic jaundice in full-term compatible newborns
[10, 13]. Table IV shows that the incidence of
clinically significant jaundice (serum bilirubin
^10 — 12 mg/dl) in ABO compatible newborns is
much lower in Negro than in White population.
In Negro populations the frequency of BA-ADA
2-1 phenotype is about one fifth of that observed
in Whites. Assuming that interactions similar to
those observed in Italian populations are also act-
ing in the genetic background of Blacks, from the
data in table IV one can calculate that more than
one third of the difference in the incidence of
neonatal jaundice between the two ethnic groups
may be explained by the difference in the fre-
quency of ACPi BA-ADA 2-1 genotype. The prac-
tical absence of ACPi phenotype CA in Blacks
may also contribute to the low incidence of jaun-
dice in this ethnic group.
Genes for ACPi and ADA are on chromosomes
2 and 20 respectively; therefore, no linkage effects
are involved in the interaction between these po-
lymorphisms.
The possibility that effects on jaundice may be
due to genes linked to ACPi and/or ADA cannot
be excluded at present. However, since the func-
tions of ACPi and ADA suggest plausible bio-
chemical mechanisms we would favour a direct
J. Perinat. Med. 17 (1989)
Lepore et al., Enzyme variability and neonatal jaundice 199
Table IV. Frequency of ACPi B A-ADA 2-1 phenotype in White and Negro populations and incidence of clinically




Approximate % Expected %
gene frequencies frequencies
Pa Pb ADA2 of ACPi BA-
ADA 2-1
phenotype
27 67 7 4.7






















involvement of ACPi and ADA in the phenome-
non presently described.
It is likely that metabolic variability due to enzyme
polymorphism may significantly contribute to
modulation of bilirubin metabolism in the critical
phase of adaptation to extrauterine life. Enzyme
of purine nucleotide metabolism (including ADA),
ACPi and flavoenzymes may represent a polygenic
complex influencing bilirubin levels in the first few
days of life and probably also other developmental
variables.
Abstract
A sample of children treated by phototherapy during
the neonatal period has been studied in the population
of Penne (South Eastern Italy) in order to confirm the
association previously reported in newborns from the
population of Rome between neonatal jaundice and
phenotypes of adenosine deaminase (ADA) and acid
phosphatase (ACPi).
The present data confirm that the incidence of clinically
relevant jaundice is much greater in newborns of phen-
otype ACPi BA carrying ADA2 allele than in other
infants.
Since ACPi probably acts as flavin mononucleotide
phosphatase and is modulated by purine nucleotides, it
is likely that enzymes of purine nucleotide metabolism
(including ADA), ACPi and flavoenzymes (including
gluthatione reductase and enzymes of Krebs cycle), may
represent a polygenic complex influencing bilirubin lev-
els in the first few days of life.
Keywords: Acid phosphatase, adenosine deaminase, enzyme polymorphism, neonatal jaundice.
Zusammenfassung
Enzymvariabilität und neonatale Gelbsucht — zur Rolle
der Adenosin-Deaminase und Säurephosphatase
In früheren Untersuchungen konnte in der Bevölkerung
von Rom bei reifgeborenen Kinder mit Blutgruppen-
Kompatibilität folgendes Phänomen beobachtet werden:
Neugeborene mit ACPi Phänotyp BA, Träger von
ADA2-Allelen zeigten häufiger eine Gelbsucht als andere
Kinder (ACPi = Säurephosphatase Locus l, ADA2 =
Adenosin-Deaminase). Diese Beobachtung ist nun an
einer weiteren Untersuchungsreihe von Kindern aus
einer anderen italienischen Population bestätigt worden.
Wir untersuchten 56 Kinder, die in der Neonatalphase
eine Phototherapie erhielten und 141 Neugeborene ohne
Gelbsucht aus der Region von Penne (Südosten von
Italien). Zum Vergleich werden die Daten der 225 Kinder
aus der römischen Bevölkerung gezeigt.
Tabellen II u. III, sowie Abbildung 2 zeigen, daß in
beiden Populationen ACP! Phänotyp BA, Träger von
ADA2-Allelen positiv korreliert ist mit einer klinisch
bedeutsamen Gelbsucht. Der Anteil der Kinder mit der
o. gen. Konstellation an Neugeborenen mit Hyperbili-
rubinämie betrug in Rom 23.8% und in Penne 12.5%.
Bei Kindern ohne Gelbsucht war der Anteil 3.4% bzw
3.5%.
ACPi ist ein polymorphes Enzym, welches wahrschein-
lich in vivo als eine Flavin-Mononucleotid-Phosphatase
fungiert. Von daher könnte es die Aktivität im Krebs-
Zyklus modulieren und andere wichtige Enzyme wie die
Glutathionreductase beeinflussen, ein Flavoenzym, das
eine Schlüsselrolle bei der Formerhaltung der roten Blut-
körperchen spielt. Die enzymatische Aktivität der ACPi
wird durch Purine moduliert (d.h. aktiviert oder inhi-
J. Perinat. Med. 17 (1989)
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biert). Der wichtigste Aspekt dieses Befundes ist die
Tatsache, daß bei der quantitativen Variation der ACPi-
Aktivität die Wirkung der Alloenzyme in der Rangord-
nung pa < pb < pc zunimmt, während hinsichtlich der
Modulation der Purine die Wirkung der Alloenzyme mit
pc < pa < pb oder pb < pa < pc einzuordnen ist.
ADA ist ein polymorphes Enzym, welches die De-Ami-
nierung von Adenosin zu Inosin katalysiert. Die Syn-
these wird durch einen autosomalen Locus mit zwei
kodominanten Allelen ADA1 und ADA2 kontrolliert.
Die enzymatische Aktivität nimmt in der Reihenfolge
ADA1 > ADA2 ab. Daß eine Interaktion zwischen ACPi
und ADA möglich ist, wurde durch die Beobachtung
nahegelegt, daß Adenosin keinen bedeutsamen Einfluß
auf die ACPi-Aktivität hat, während dagegen Inosin als
relativ starker Aktivator wirkt.
Ethnische Faktoren könnten den Schweregrad einer phy-
siologischen Hyperbilirubinämie bei Reifgeborenen be-
einflussen. Tatsächlich ist die Inzidenz einer klinisch
bedeutsamen Gelbsucht bei Neugeborenen mit ABO-
Kompabilität unter Negern viel niedriger als in der wei-
ßen Population. Da die Frequenz von -Personen, die
ADA2-Träger sind, unter Schwarzen ebenfalls geringer
ist als unter Weißen, könnte dies zu der unterschiedlichen
Inzidenz der neonatalen Gelbsucht bei diesen beiden
ethnischen Gruppen beitragen (Tabelle IV).
Wahrscheinlich wirkt die metabolische Variabilität, be-
dingt durch den Enzympolymorphismus, entscheidend
auf die Modulation des Bilirubinmetabolismus in der
kritischen Adaptationsphase an das extrauterine Leben
ein. Enzyme des Purinstoffwechsels (incl. ADA), ACPi
und Flavoenzyme widerspiegeln einen polygenen Kom-
plex, der die Bilirubinspiegel in den ersten Lebenstagen
sowie vielleicht auch andere Variabilitäten in der Ent-
wicklung beeinflußt.
Schlüsselwörter: Adenosin-Deaminase, Enzympolymorphismus, neonatale Gelbsucht, Säurephosphatase.
Resume
Variabilite enzymatique et ictere neonatal. Role de l'ade-
nosine deaminase et de la phosphatase acide
Des etudes anterieures sur la population de Rome ont
montre que chez les nouveaux-nes compatibles a terme,
l'incidence d'icteres chez les nouveaux-nes de phenotype
ACPi (phosphatase acide locus 1) portant Fallele
ADA2 (adenosine deaminase) est beaucoup plus elevee
que chez les autres enfants. Cette observation est main-
tenant confirmee dans une nouvelle serie d'enfants issus
d'autre population italienne.
On a etudie un echantillon de 56 enfants traites par
phototherapie en periode neonatale et un echantillon de
141 nouveaux-nes sans ictere provenant de la population
de Penne (Sud Est de FItalie). A titre de comparaison,
les donnees des series anterieure de 225 enfant romains
sont rapportees.
Les tableaux II et III ainsi que la figure 2 montrent que
dans les 2 populations le phenotype ACPi BA sortant
Fallele ADA2 est associe positivement avec lictere neo-
natal clinique.
Parmi les enfants icteriques la proportion de Phenotype
ACPi BA portant Fallele ADA2 est de 23,8% ä Rome
et de 12,5% ä Penne; Parmi les enfants sans ictere, les
proportions sont restpectivement de 3,4% et de 3,5%.
ACPi est une enzyme polymorphique qui agit vraisem-
blablement in vivo comme une phosphatase mononu-
cleotide flavine; eile peut done moduler Factivite du cycle
de Krebs et d'autres enzymes importantes telles que la
glutathion reductase, flavoenzyme qui exerce un röle cle
dans la maintenance de Fintegrite des globules rouges.
L'activite enzymatique de FACPi est modulee (activation
ou inibition) par les purines. L'aspect le plus important
de ces elements est le fait que pour la variation quanti-
tative de l'activite ACPi, la contribution des alloenzymes
augmente dans l'ordre pa < pb < pc alors que pour Feffet
de modulation des purines, la contribution des alloen-
zymes peut etre soit pc < pa < pb soit pb < pa < pc.
ADA est une enzyme polymorphique qui catalyse la
desamination d'adenosine en inosine. Sa Synthese est
controlee par un locus autosomique avec deux alleles
codominants ADA1 et ADA2. L'activite enzymatique
diminue dans l'ordre ADA1 > ADA2. L'etude d'une
interaction possible entre ACPi et ADA a ete suggere
par Fobservation du fait que Fadenosine ne manifeste
pas d'effets appreciables sur Factivite ACPi, alors que,
au contraire, Finosine est un activateur relativement
puissant.
Des facteurs ethniques peuvent affecter la severite de
Fictere physiologique chez les nouveaux-nes compatibles
ä terme. En fait, l'incidence de Fictere significatif clini-
quement chez les nouveaux-nes compatibles dans le sy-
steme ABO est beaucoup plus faible chez les noirs que
chez les blancs. Puisque la frequence des sujets BA
portant ADA2 est egalement beaucoup plus faible chez
les noirs que chez les blancs, cela peut contribuer a la
difference de l'incidence de Fictere neonatal entre les
deux groupes ethniques (tableau IV).
II est vraisembable que la variabilite metabolique secon-
daire au polymorphisme enzymatique peut contribuer
significativement ä une modulation du metabolisme de
la bilirubine pendant la phase critique d'adaptation ä la
vie extrauterine. Les enzymes du metabolisme des nu-
cleotides puriniques (y compris ADA), ACPi et Fla-
voenzymes represented un complexe polygenique qui
influence les taux de bilirubine au cours des premiers
jours de vie et vraisemblablement egalement d'autres
variables developpementales.
Mots-cles: Adenosine deaminase, ictere neonatal, phosphatases acide, polymorphisme enzymatique.
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